Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

Now Viewing

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Video content above is prompted by the following:

• What are the current challenges in translating clinical trial results into real-world practice for melanoma treatment? How can this process be streamlined?
• Please discuss any other data in melanoma released at ASCO 2024 that you find noteworthy to share with colleagues. (Please be prepared to discuss during the interview)
• Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of melanoma? What can we look forward to through the end of the year and beyond?